Project Details
Description
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors
| Status | Finished |
|---|---|
| Effective start/end date | 9/22/22 → 6/5/23 |
Funding
- FATE THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.